During severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the chance of suffering acute kidney injury (AKI) increases significantly. Therefore, the present study aimed to conduct a comprehensive pharmacotherapeutic evaluation of AKI in patients with coronavirus. From July to August 2021, a retrospective cohort study was conducted on coronavirus patients hospitalized at the Institute of Kidney Diseases, Hayatabad Medical Complex in Peshawar, Pakistan. Demographics, diagnosis, laboratory values, vital signs, and hospital care were all utilized to extract data. Parametric statistics, including regression analysis, one-way ANOVA, and Kruskal-Wallis, were used to examine the association between independent variables. Data from 595 coronavirus patients whose PCR results met predetermined criteria were collected. The most common symptoms among the patients were fever (n = 575 [96.6%]), lack of breathing (n = 570 [95.8%]), dry cough (n = 449 [75.5%]), and body pains (n = 129 [21.7%]). During their hospitalization, most patients were taking multiple medications. Overall, it was shown that coronavirus patients with stage III AKI had a significant reduction in most laboratory indicators. Compared with those without AKI, the mortality rate for AKI patients was 42% [0.418 [0.269–0.632], P < 0.001]. Intravenous dexamethasone was associated with a 96% reduction in mortality (1.968 [1.277–3.033], P = 0.002). To prevent the appearance of AKI in coronavirus patients, a clinician’s top priority is to maintain appropriate oxygen saturation and refrain from using nephrotoxic medications while the patient is in the hospital.
